| pubmed-article:11205463 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11205463 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:11205463 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11205463 | lifeskim:mentions | umls-concept:C0029921 | lld:lifeskim |
| pubmed-article:11205463 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:11205463 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:11205463 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:11205463 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:11205463 | pubmed:dateCreated | 2001-2-2 | lld:pubmed |
| pubmed-article:11205463 | pubmed:abstractText | We performed a trial using the combination of epirubicin 50 mg/m2/day 1, carboplatinum AUC 5/day 1 and continuous 5-fluorouracil (5-FU) 200 mg/m2/day (every 4 weeks for 6 months) to confirm the efficacy and low toxicity profile of this regimen in breast cancer. In 51 patients with metastatic (n = 33) or locally advanced (n = 18) breast cancer the overall response rate was 86% (95% confidence interval (95% CI): 73%-94%): 94% in locally advanced and 81% metastatic disease. Grade 3-4 toxicity was low: 4% of patients presented with febrile neutropenia, 16% with severe palmar-plantar syndrome, 10% with Port-a-cath thrombosis. This study confirms the high efficacy of infusional 5-FU-based regimens and justifies further research into novel promising oral 5-FU derivatives. | lld:pubmed |
| pubmed-article:11205463 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11205463 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11205463 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11205463 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11205463 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11205463 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11205463 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11205463 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:11205463 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:11205463 | pubmed:author | pubmed-author:MermillodBB | lld:pubmed |
| pubmed-article:11205463 | pubmed:author | pubmed-author:MagliAA | lld:pubmed |
| pubmed-article:11205463 | pubmed:author | pubmed-author:BonnefoyXX | lld:pubmed |
| pubmed-article:11205463 | pubmed:author | pubmed-author:SchaferPP | lld:pubmed |
| pubmed-article:11205463 | pubmed:author | pubmed-author:SappinoA PAP | lld:pubmed |
| pubmed-article:11205463 | pubmed:author | pubmed-author:AnguenotJ LJL | lld:pubmed |
| pubmed-article:11205463 | pubmed:author | pubmed-author:AnchisiSS | lld:pubmed |
| pubmed-article:11205463 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11205463 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:11205463 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11205463 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11205463 | pubmed:pagination | 1557-61 | lld:pubmed |
| pubmed-article:11205463 | pubmed:dateRevised | 2006-4-24 | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:meshHeading | pubmed-meshheading:11205463... | lld:pubmed |
| pubmed-article:11205463 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11205463 | pubmed:articleTitle | Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen. | lld:pubmed |
| pubmed-article:11205463 | pubmed:affiliation | Division d'Oncologie, H pital Cantonal Universitaire de Genève, Switzerland. Anne.Huegli@hcuge.ch | lld:pubmed |
| pubmed-article:11205463 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11205463 | pubmed:publicationType | Clinical Trial | lld:pubmed |
